This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Citron, D. M. Articles by Appleman, M. D. Search for Related Content PubMed PubMed Citation Articles by Citron, D. M. Articles by Appleman, M. D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2001, p. 345-348, Vol. 45, No. 1
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.1.345-348.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Comparative In Vitro Activities of ABT-773 against 362 Clinical Isolates of Anaerobic Bacteria

Diane M. Citron^1,* and Maria D. Appleman^1,2

Microbial Research Laboratory¹ and Department of Pathology,² Los Angeles County- University of Southern California Medical Center, Los Angeles, California

Received 7 March 2000/Returned for modification 29 July 2000/Accepted 17 October 2000

The activity of ABT-773, a novel ketolide antibiotic, against clinical isolates of anaerobic bacteria was determined and compared to the activities of other antimicrobial agents. MICs at which 90% of isolates were inhibited (MIC₉₀s) were 0.06 µg/ml for Actinomyces spp., Clostridium perfringens, Peptostreptococcus spp., Propionibacterium spp., and Porphyromonas spp. The MIC₅₀s and MIC₉₀s were 0.06 and >32 µg/ml, respectively, for Eubacterium spp., Lactobacillus spp., Clostridium difficile, and Clostridium ramosum. The MIC₉₀ for Bilophila wadsworthia, Bacteroides ureolyticus, and Campylobacter gracilis was 1 µg/ml, and that for Prevotella bivia and other Prevotella spp. was 0.5 µg/ml. The MIC₉₀ for Fusobacterium nucleatum was 8 µg/ml, and that for Fusobacterium mortiferum and Fusobacterium varium was >32 µg/ml. The MIC₉₀s for the Bacteroides fragilis group were as follows: for B. fragilis, 8 µg/ml; for Bacteroides thetaiotaomicron, Bacteroides ovatus, Bacteroides distasonis, and Bacteroides uniformis, >32 µg/ml; and for Bacteroides vulgatus, 4 µg/ml. Telithromycin MICs for the B. fragilis group were usually 1 to 2 dilutions higher than ABT-773 MICs. For all strains, ABT-773 was more active than erythromycin by 4 or more dilutions, and for some strains this drug was more active than clindamycin.

---

^* Corresponding author. Mailing address: LAC+USC Medical Center, General Labs Bldg., Room 2G-24, 1801 East Marengo St., Los Angeles, CA 90033. Phone: (323) 226-3749. Fax: (323) 226-7021. E-mail: dcitron{at}hsc.usc.edu.

---

Antimicrobial Agents and Chemotherapy, January 2001, p. 345-348, Vol. 45, No. 1
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.1.345-348.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

This article has been cited by other articles:

• Finegold, S. M., Molitoris, D., Phan, V. T., Vaisanen, M.-L., Wexler, H. M. (2002). Activities of ABT-773 against Microaerophilic and Fastidious Organisms. Antimicrob. Agents Chemother. 46: 2716-2719 [Abstract] [Full Text]  
• Pendland, S. L., Neuhauser, M. M., Prause, J. L. (2002). In vitro bactericidal activity and post-antibiotic effect of ABT-773 versus co-amoxiclav against anaerobes. J Antimicrob Chemother 49: 879-881 [Full Text]  
• Goldstein, E. J. C., Conrads, G., Citron, D. M., Merriam, C. V., Warren, Y., Tyrrell, K. (2001). In Vitro Activities of ABT-773, a New Ketolide, against Aerobic and Anaerobic Pathogens Isolated from Antral Sinus Puncture Specimens from Patients with Sinusitis. Antimicrob. Agents Chemother. 45: 2363-2367 [Abstract] [Full Text]